search
Back to results

A Study of Baclofen ER (CURE)

Primary Purpose

Cocaine Dependence

Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Baclofen ER
Placebo
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cocaine Dependence focused on measuring Cocaine, Treatment, fMRI, Outcomes

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Physically healthy cocaine-dependent (based on DSM-IV- TR criteria) male or female aged 18-60 yrs, voluntarily seeking treatment for cocaine dependence.
  2. Females must be non-pregnant, non- lactating and either be of non-childbearing potential (i.e. sterilized via hysterectomy or bilateral tubal ligation or at least 1 year post-menopausal) or of child bearing potential, but practicing a medically acceptable method of birth control. Examples of medically acceptable methods for this protocol include barrier (diaphragm or condom) with spermicide, an intrauterine device (IUD), oral contraceptives, a levonorgestrel implant, intrauterine progesterone contraceptive system, medroxyprogesterone acetate contraceptive injection, and abstinence.
  3. Reading level at or above eighth grade.
  4. Participants provide voluntary informed consent.
  5. Smoking is primary route of cocaine administration.
  6. Available for an inpatient stay.

Exclusion Criteria:

  1. Participation in clinical trial and receipt of investigational drug(s) during previous 60 days, except as explicitly approved by the Principal Investigator.
  2. Clinically significant cardiovascular, hematologic, hepatic, renal, neurological or endocrinological abnormalities.
  3. History of serious head trauma or injury causing loss of consciousness that lasted more than 3 minutes or associated with skull fracture or inter-cranial bleeding or abnormal MRI.
  4. Presence of magnetically active prosthetics, plates, pins, broken needles, permanent retainer, bullets, etc. in patient's body (unless a radiologist confirms that its presence is unproblematic). An x-ray may be obtained to determine eligibility.
  5. Claustrophobia or other medical condition that disables the participant from lying in the MRI for approximately 60 minutes.
  6. Current or prior gambling problems (assessed by participants self-report)
  7. Non-removable skin patches
  8. Have received medication that could interact adversely with baclofen, including muscle relaxants (including tricyclic antidepressants), antiseizure medication, CNS depressants (tranquilizers, sleeping pills), MAO inhibitors), within the time of administration of study agent based on the study physician's guidance (e.g. 5 half lives)
  9. Have known or suspected hypersensitivity to baclofen.
  10. Be taking baclofen for any reason currently or during the past year.

Sites / Locations

  • Center for the Studies of Addiction

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Baclofen ER versus Placebo

Placebo versus Baclofen ER

Arm Description

Baclofen ER versus Placebo (sugar pill)

Participants will receive either placebo (sugar pill) or Baclofen ER

Outcomes

Primary Outcome Measures

Urines positive for benzoylecgonine (BE), (a metabolite of cocaine)
The primary clinical outcome is number of cocaine-use days (assessed by urines positive for benzoylecgonine (BE), a metabolite of cocaine) during the outpatient treatment and follow-up phases of the study.

Secondary Outcome Measures

Full Information

First Posted
November 19, 2013
Last Updated
September 6, 2016
Sponsor
University of Pennsylvania
search

1. Study Identification

Unique Protocol Identification Number
NCT02003664
Brief Title
A Study of Baclofen ER
Acronym
CURE
Official Title
A Randomized Placebo-controlled Study of Baclofen ER on Brain and Behavioral Outcomes in Cocaine Dependence
Study Type
Interventional

2. Study Status

Record Verification Date
September 2016
Overall Recruitment Status
Withdrawn
Why Stopped
This study never started due to delays in medication development
Study Start Date
November 2013 (undefined)
Primary Completion Date
November 2014 (Anticipated)
Study Completion Date
November 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase II, randomized, double-blind, placebo-controlled study that will examine the efficacy of extended-release baclofen (Baclofen ER) for the treatment of cocaine dependence. The primary study outcome will be urines positive for benzoylecgonine (BE), a metabolite of cocaine, submitted during outpatient treatment (12-week) and follow-up (12-week). To examine brain mechanisms of relapse/recovery, participants will complete fMRI sessions before, during, and after treatment. Brain responses to specific probes of reward and inhibition will be used as biomarkers predicting drug use during and after the treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine Dependence
Keywords
Cocaine, Treatment, fMRI, Outcomes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Baclofen ER versus Placebo
Arm Type
Active Comparator
Arm Description
Baclofen ER versus Placebo (sugar pill)
Arm Title
Placebo versus Baclofen ER
Arm Type
Placebo Comparator
Arm Description
Participants will receive either placebo (sugar pill) or Baclofen ER
Intervention Type
Drug
Intervention Name(s)
Baclofen ER
Intervention Description
Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Sugar pill
Intervention Description
Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
Primary Outcome Measure Information:
Title
Urines positive for benzoylecgonine (BE), (a metabolite of cocaine)
Description
The primary clinical outcome is number of cocaine-use days (assessed by urines positive for benzoylecgonine (BE), a metabolite of cocaine) during the outpatient treatment and follow-up phases of the study.
Time Frame
up to 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Physically healthy cocaine-dependent (based on DSM-IV- TR criteria) male or female aged 18-60 yrs, voluntarily seeking treatment for cocaine dependence. Females must be non-pregnant, non- lactating and either be of non-childbearing potential (i.e. sterilized via hysterectomy or bilateral tubal ligation or at least 1 year post-menopausal) or of child bearing potential, but practicing a medically acceptable method of birth control. Examples of medically acceptable methods for this protocol include barrier (diaphragm or condom) with spermicide, an intrauterine device (IUD), oral contraceptives, a levonorgestrel implant, intrauterine progesterone contraceptive system, medroxyprogesterone acetate contraceptive injection, and abstinence. Reading level at or above eighth grade. Participants provide voluntary informed consent. Smoking is primary route of cocaine administration. Available for an inpatient stay. Exclusion Criteria: Participation in clinical trial and receipt of investigational drug(s) during previous 60 days, except as explicitly approved by the Principal Investigator. Clinically significant cardiovascular, hematologic, hepatic, renal, neurological or endocrinological abnormalities. History of serious head trauma or injury causing loss of consciousness that lasted more than 3 minutes or associated with skull fracture or inter-cranial bleeding or abnormal MRI. Presence of magnetically active prosthetics, plates, pins, broken needles, permanent retainer, bullets, etc. in patient's body (unless a radiologist confirms that its presence is unproblematic). An x-ray may be obtained to determine eligibility. Claustrophobia or other medical condition that disables the participant from lying in the MRI for approximately 60 minutes. Current or prior gambling problems (assessed by participants self-report) Non-removable skin patches Have received medication that could interact adversely with baclofen, including muscle relaxants (including tricyclic antidepressants), antiseizure medication, CNS depressants (tranquilizers, sleeping pills), MAO inhibitors), within the time of administration of study agent based on the study physician's guidance (e.g. 5 half lives) Have known or suspected hypersensitivity to baclofen. Be taking baclofen for any reason currently or during the past year.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anna Rose Childress, PhD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for the Studies of Addiction
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study of Baclofen ER

We'll reach out to this number within 24 hrs